Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lyophilized Injectable Drugs Market

Lyophilized Injectable Drugs Market Trends

Report ID: GMI5371
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Lyophilized Injectable Drugs Market Trends

The surging count of product approvals for lyophilized injectable drugs will complement the industry expansion. The robust presence of major market players has led to the increase in product availability and accessibility. The rising number of several clinical studies undertaken by various organizations for securing product approvals to cater to the extended applications of lyophilized injectables drugs for treating cancer and other diseased patients.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lyophilized injectable drugs industry size was more than USD 280 billion in 2022 and will record 13.5% CAGR by 2032 ascribing to the increasing research, development, as well as commercialization of novel drugs to cater to varied disease treatment.

Anti-infective lyophilized injectable drugs market size is anticipated to exceed USD 311 billion by 2032 due to the surging incidences of various infectious diseases, such as HIV, herpes simplex virus, influenza, and hepatitis virus.

North America held over 47% of the industry share in 2022 owing to the rising prevalence of chronic diseases and the surging need for well-established healthcare infrastructure in the region.

Some of the leading lyophilized injectable drugs industry players are Novo Nordisk A/S, Sanofi, Aurobindo Pharmaceuticals, Fresenius SE & Co. KGaA (Fresenius Kabi), Merck & Co., Inc, Zydus Group, Vetter Pharma, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services.